SPRB
Spruce BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that TA-ERT has a clearer FDA path after the Type B meetings, the Q4 2026 BLA target is achieved, and investors begin underwriting first-mover value in MPS IIIB plus access to milestone-linked debt capital.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +4.8.
What can break
Additional Avenue debt tranches are milestone-gated rather than fully committed upfront.
Momentum
18
Value
41
Sentiment
97
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $72.00 · Bull $120.00 · Bear $34.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $205.75
Why
Momentum18 · Δ7d -2.0
Value41 · Δ7d +0.1
Sentiment97 · Δ7d +4.8
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
18
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.0
Δ21d
-8.3
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
97
33% active weight
Current posture
7d trendImproving
Δ7d
+4.8
Δ21d
+23.3
Why this grade
Composite grade C. Momentum 18.0 / Value 41.1 / Sentiment 96.9
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$139.54M
Beta
3.59
Shares Out
1.07M
P/E (TTM) · Derived
-1.3
P/S (TTM)
126.11
P/FCF (TTM) · Derived
-1.57
Rev YoY
-100.0%
EPS YoY
+7.4%
Gross Margin
-
Op Margin
-7100.0%
Net Debt
-$37.01M
Current Ratio
1.54
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology